

SENTINEL ARTICLES IN GYNECOLOGIC CANCER

Endometrial Cancer

Disclaimer: This list represents a collection of articles identified by members of SGO as important in the context of specific disease sites, it is not meant to serve as a specific tool of study for examinations and has not been approved by governing organizations in education

1. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. *Cancer*. 1985;56(2):403–412.
<https://pubmed.ncbi.nlm.nih.gov/4005805/>
2. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. *Cancer*. 2006;106(4):812–819. <https://pubmed.ncbi.nlm.nih.gov/16400639/>
3. Chan JK, Loizzi V, Youssef M, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. *Gynecol Oncol*. 2003;90(1):181–185.
<https://pubmed.ncbi.nlm.nih.gov/12821361/>
4. Geisler JP, Geisler HE, Melton ME, et al. What staging surgery should be performed on patients with uterine papillary serous carcinoma? *Gynecol Oncol*. 1999;74(3):465–467.
<https://pubmed.ncbi.nlm.nih.gov/10479511/>
5. Mariani A, Webb MJ, Keeney GL, et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? *Am J Obstet Gynecol*. 2000; 182(6):1506–1519.
<https://pubmed.ncbi.nlm.nih.gov/10871473/>
6. Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. *Gynecol Oncol*. 1990;38(1):46–48. <https://pubmed.ncbi.nlm.nih.gov/2354826/>

7. Doering DL, Barnhill DR, Weiser EB, et al. Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma. *Obstet Gynecol*. 1989;74(6):930–933.
<https://pubmed.ncbi.nlm.nih.gov/2586959/>
8. Franchi M, Ghezzi F, Melpignano M, et al. Clinical value of intraoperative gross examination in endometrial cancer. *Gynecol Oncol*. 2000;76(3):357–361. <https://pubmed.ncbi.nlm.nih.gov/10684710/>
9. Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. *J Clin Oncol*. 2005;23:3668–3675.
<https://pubmed.ncbi.nlm.nih.gov/15738538/>
10. Chan JK, Cheung MK, Huh WK, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. *Cancer*. 2006;107(8):1823–1830.
<https://pubmed.ncbi.nlm.nih.gov/16977653/>
11. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. *Gynecol Oncol*. 1995;56:29–33.
<https://pubmed.ncbi.nlm.nih.gov/7821843/>
12. Chan JK, Kapp DS, Cheung MK, et al. The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. *Br J Cancer*. 2007;97(5):605–611.
<https://pubmed.ncbi.nlm.nih.gov/17667929/>
13. Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. *J Clin Oncol*. 2004;22(7):1234–1241.
<https://pubmed.ncbi.nlm.nih.gov/15051771/>
14. Nelson G, Randall M, Sutton G, et al. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. *Gynecol Oncol*. 1999;75(2):211–214.
<https://pubmed.ncbi.nlm.nih.gov/10525373/>

15. Ayhan A, Taskiran C, Celik C, et al. Surgical stage III endometrial cancer: analysis of treatment outcomes, prognostic factors and failure patterns. *Eur J Gynaecol Oncol.* 2002;23(6):553–556.
<https://pubmed.ncbi.nlm.nih.gov/12556104/>
16. Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group study LAP-2. *J Clin Oncol.* 2009;27(32):5331–5336. <https://pubmed.ncbi.nlm.nih.gov/19805679/>
17. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. *J Natl Cancer Inst.* 2008;100(23):1707–1716. <https://pubmed.ncbi.nlm.nih.gov/19033573/>
18. ASTEC/EN.5 Study Group; Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. *Lancet.* 2009;373(9658):137–148.
<https://pubmed.ncbi.nlm.nih.gov/19070891/>
19. Kitchener H, Swart AM, Qian Q, et al; ASTEC study group. Efficacy of systemic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. *Lancet.* 2009;373(9658):125–136. <https://pubmed.ncbi.nlm.nih.gov/19070889/>
20. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1991;40(1):55–65. <https://pubmed.ncbi.nlm.nih.gov/1989916/>
21. Disaia PJ. Predicting parametrial involvement in endometrial cancer: is this the end for radical hysterectomies in stage II endometrial cancers? *Obstet Gynecol.* 2010;116(5):1016–1017.
<https://pubmed.ncbi.nlm.nih.gov/20966681/>
22. Greer BE, Hamberger AD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. *Gynecol Oncol.* 1983;16(3):365–373. <https://pubmed.ncbi.nlm.nih.gov/6654180/>
23. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. *Gynecol Oncol.* 1994;54(3):264–268. <https://pubmed.ncbi.nlm.nih.gov/8088602/>

24. Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. *Gynecol Oncol*. 2001;81(1):92–99.
<https://pubmed.ncbi.nlm.nih.gov/11277657/>
25. Shih KK, Yun E, Gardner GJ, et al. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. *Gynecol Oncol*. 2011;122(3):608–611. <https://pubmed.ncbi.nlm.nih.gov/21664663/>
26. Kelly MG, O’Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. *Gynecol Oncol*. 2005;98(3):353–359. <https://pubmed.ncbi.nlm.nih.gov/16005947/>
27. Tanner EJ, Leitao MM Jr, Garg K, et al. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. *Gynecol Oncol*. 2011;123(3):548–552.
<https://pubmed.ncbi.nlm.nih.gov/21945551/>
28. Reed NS, Mangioni C, Malmström H, et al., Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). *Eur J Cancer*. 2008 Apr;44(6):808-18. doi: 10.1016/j.ejca.2008.01.019. Epub 2008 Apr 2. Erratum in: *Eur J Cancer*. 2008 Jul;44(11):1612. PMID: 18378136.
<https://pubmed.ncbi.nlm.nih.gov/18378136/>
29. Homesley HD, Filiaci V, Markman M. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. *J Clin Oncol*. 2007; 25(5):526–531. <https://pubmed.ncbi.nlm.nih.gov/17290061/>
30. Awtrey CS, Cadungog MG, Leitao MM, et al. Surgical resection of recurrent endometrial carcinoma. *Gynecol Oncol*. 2006;102(3):480–488. <https://pubmed.ncbi.nlm.nih.gov/16490236/>
31. Scudder SA, Liu PY, Wilczynski SP, et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. *Gynecol Oncol*. 2005;96(3):610–615. <https://pubmed.ncbi.nlm.nih.gov/15721401/>

32. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. *J Clin Oncol*. 1999;17(6):1736–1744. <https://pubmed.ncbi.nlm.nih.gov/10561210/>
33. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2010;116(1):15–20. <https://pubmed.ncbi.nlm.nih.gov/19840887/>
34. Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol*. 2006;24:587–592. <https://pubmed.ncbi.nlm.nih.gov/16446331/>
35. Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. *Obstet Gynecol*. 2010;116(5):1141–1149. <https://pubmed.ncbi.nlm.nih.gov/20966700/>
36. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. *Obstet Gynecol*. 1980;56(4):419–427. <https://pubmed.ncbi.nlm.nih.gov/6999399/>
37. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Postoperative Radiation Therapy in Endometrial Carcinoma. *Lancet*. 2000;355(9213):1404–1411. <https://pubmed.ncbi.nlm.nih.gov/10791524/>
38. Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. *Int J Radiat Oncol Biol Phys*. 2011;81(4):e631–e638. <https://pubmed.ncbi.nlm.nih.gov/21640520/>
39. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2004;92(3):744–751. <https://pubmed.ncbi.nlm.nih.gov/14984936/>

40. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet*. 2010;375(9717):816–823.
<https://pubmed.ncbi.nlm.nih.gov/20206777/>
41. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. *Gynecol Oncol*. 2008;108(1):226–233.
<https://pubmed.ncbi.nlm.nih.gov/17996926/>
42. Todo Y, Kato H, Kaneuchi M et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. *Lancet*. 2010;375(9721):1165–1172.
<https://pubmed.ncbi.nlm.nih.gov/20188410/>
43. Cohen CJ, Bruckner HW, Deppe G, et al. Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Obstet Gynecol*. 1984;63(5):719–726.
<https://pubmed.ncbi.nlm.nih.gov/6371627/>
44. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 1994;12(7):1408–1414.
<https://pubmed.ncbi.nlm.nih.gov/8021731/>
45. Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. *Gynecol Oncol*. 2006;100(2):349–354. <https://pubmed.ncbi.nlm.nih.gov/16213007/>
46. Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2005;97:755–763. <https://pubmed.ncbi.nlm.nih.gov/15913742/>
47. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 2004;22(19):3902–3908. <https://pubmed.ncbi.nlm.nih.gov/15459211/>

48. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 2006;24(1):36–44. <https://pubmed.ncbi.nlm.nih.gov/16330675/>
49. Gallion HH, Brunetto VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 2003;21(20):3808–3813. <https://pubmed.ncbi.nlm.nih.gov/14551299/>
50. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin 1 cisplatin versus doxorubicin 1 24-h paclitaxel 1 filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. *Ann Oncol*. 2004;15(8):1173–1178. <https://pubmed.ncbi.nlm.nih.gov/15277255/>
51. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 2004;22(11):2159–2166. <https://pubmed.ncbi.nlm.nih.gov/15169803/>
52. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2009;112:543–552. <https://pubmed.ncbi.nlm.nih.gov/19108877/>
53. Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecology Oncology Group study. *Gynecol Oncol*. 2012;125:771–773. [https://www.gynecologiconcology-online.net/article/S0090-8258\(12\)00228-4/pdf](https://www.gynecologiconcology-online.net/article/S0090-8258(12)00228-4/pdf)
54. Mundt AJ, McBride R, Rotmensch J, et al. Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys*. 2001;50(5):1145–1153. <https://pubmed.ncbi.nlm.nih.gov/11483323/>

55. Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2003;88(3):277–281. <https://pubmed.ncbi.nlm.nih.gov/12648575/>
56. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2007;106(1):16–22. <https://pubmed.ncbi.nlm.nih.gov/17574073/>
57. Nout, R. A., Smit, V. T., Putter, H., Jürgenliemk Schulz, I. M., Jobsen, J. J., Lutgens, L. C., ... Creutzberg, C. L. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet* 2010, 375(9717), 816-823. <https://pubmed.ncbi.nlm.nih.gov/20206777/>
58. Small, W., Beriwal, S., Demanes, D. J., Dusenbery, K. E., Eifel, P., Erickson, B., ... Gaffney, D. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. *Brachytherapy* 2012, 11(1), 58-67. <https://pubmed.ncbi.nlm.nih.gov/22265439/>
59. Kandoth, C., Schultz, N., Cherniack, A. D., Akbani, R., Liu, Y., Shen, H., ... Levine, D. A. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013, 497(7447), 67-73. <https://pubmed.ncbi.nlm.nih.gov/23636398/>
60. Slomovitz, B. M., Jiang, Y., Yates, M. S., Soliman, P. T., Johnston, T., Nowakowski, M., ... Coleman, R. L. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. *J Clin Oncol* 2015, 33(8), 930-936. <https://pubmed.ncbi.nlm.nih.gov/25624430/>
61. Paley, P. J., Veljovich, D. S., Press, J. Z., Isacson, C., Pizer, E., & Shah, C. A prospective investigation of fluorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging. *Am J Obstet Gynecol* 2016, 215(1), 117.e1-117.e7. <https://pubmed.ncbi.nlm.nih.gov/26743505/>

62. Ott, P. A., Bang, Y., Berton Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., ... Soria, J. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. *J Clin Oncol* 2017, 35(22), 2535-2541. <https://pubmed.ncbi.nlm.nih.gov/28489510/>
63. Rossi, E. C., Kowalski, L. D., Scalici, J., Cantrell, L., Schuler, K., Hanna, R. K., ... Boggess, J. F. (2017). A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. *Lancet Oncol* 2017, 18(3), 384-392. <https://pubmed.ncbi.nlm.nih.gov/28159465/>
64. Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Santin, A. D. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. *J Clin Oncol* 2018, 36(20), 2044-2051. <https://pubmed.ncbi.nlm.nih.gov/29584549/>
65. Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orłowski R, Sachdev P, Shumaker R, Casado Herraéz A. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. *J Clin Oncol*. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13. PMID: 32167863. [KEYNOTE-146/Study 111] <https://pubmed.ncbi.nlm.nih.gov/32167863/>
66. de Boer SM, Powell ME, Mileskin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: *Lancet Oncol*. 2018. Apr;19(4):e184. PMID: 29449189 [PORTEC 3] <https://pubmed.ncbi.nlm.nih.gov/29449189/>